Status:
RECRUITING
Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss
Lead Sponsor:
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Conditions:
Sudden Sensorineural Hearing Loss
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to learn which one works to treat better in patients with sudden sensorineural hearing loss, oral or intratympanic corticosteroid treatment. The main question it ai...
Eligibility Criteria
Inclusion
- 18 years of age and older
- Unilateral sudden sensorineural hearing loss that developed within 72 hours and has lasted for 14 days or less
- Affected side PTA (500-100-2000-4000hz) should be over 50dB
- Affected side should be at least 30dB lower than healthy side in 3 frequencies
- Hearing should be symmetrical according to patient's statement before sensorineural hearing loss
- If used, steroid use should be less than 10 days
- Cerebellar and vestibular examination should be normal
Exclusion
- Having a history of hearing-related surgery other than a ventilation tube
- Having a history of previous hearing loss, fluctuating hearing or Meniere's disease, chronic inflammatory or suppurative ear disease or cholesteatoma, otosclerosis
- Being under 18 or over 80
- Having a history of physical-barotrauma
- Presence of structural or retrocochlear pathology in the examination and imaging that would explain the unilateral hearing loss
- Patients diagnosed with tuberculosis or receiving prophylactic tuberculosis treatment, diabetes mellitus, rheumatological patients, those with atherosclerotic disease, serious psychiatric patients, those receiving chemotherapy, radiotherapy or immunosuppressant treatment, pancreatitis patients, HIV, hepatitis C and B patients, those with chronic renal failure, substance abusers, those with active herpetic lesions, severe osteoporosis patients, those with hearing loss within 4 weeks after general anesthesia, those with a history of head and neck cancer.
Key Trial Info
Start Date :
May 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 10 2028
Estimated Enrollment :
214 Patients enrolled
Trial Details
Trial ID
NCT06968507
Start Date
May 20 2025
End Date
September 10 2028
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr Lütfi Kırdar City Hospital
Istanbul, Kartal, Turkey (Türkiye), 34865